Investor Overview

Investor Overview

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates (bardoxolone methyl and omaveloxolone) target an important transcription factor, called Nrf2, to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. Read More >>
RETA (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$25.43
Change (%) Stock is Up 0.07 (0.28%)
Volume48,256
Data as of 02/24/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Stock chart for: RETA.O.  Currently trading at $25.43 with a 52 week high of $41.60 and a 52 week low of $11.03.
Data provided by Nasdaq. Minimum 15 minutes delayed.

Investor Contact
Lee M. Stern, CFA
The Trout Group
Phone: (646) 378-2922
E-mail: IR@reatapharma.com